Trial Profile
A Single-Dose Study to Assess the Efficacy of Albuterol SPIROMAX in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Oct 2015
Price :
$35
*
At a glance
- Drugs Salbutamol (Primary)
- Indications Bronchoconstriction
- Focus Registrational; Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D
- 08 Sep 2015 Primary endpoint has been met. (Maximum Percentage Fall From Baseline in Forced Expiratory Volume in 1 Second (FEV1) up to 60 Minutes After the Exercise Challenge), as per an article published in the Respiratory Medicine
- 08 Sep 2015 Results published in the Respiratory Medicine
- 01 Apr 2015 According to Teva Pharmaceutical Industries media release, company receives FDA approval for ProAir RespiClick (albuterol sulfate) for treatment and prevention of bronchospasm and exercise induced bronchospasm in patients 12 age and over.